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Background and Objectives. Determination of inflammatory bowel disease activity determines further therapeutic approach and
follow-up. The aim of our study was to investigate correlation between patients’ reported symptoms and endoscopic and
histological disease activity. Methods. A cross-sectional study was conducted in consecutive newly diagnosed patients with
inflammatory bowel disease in a tertiary care referral center. The initial evaluation included patient-reported outcome for stool
frequency subscore and rectal bleeding. Endoscopic activity was determined using the Mayo scoring system for ulcerative colitis
and the Simple Endoscopic Score for Crohn’s disease. Histopathological activity was assessed using a validated numeric scoring
system. Results. We included 159 patients (63 Crohn’s disease with colonic involvement and 96 with ulcerative colitis). We
found significant correlation between the Mayo endoscopic subscoring system and histology activity in ulcerative colitis, while
no correlation was found in patients with Crohn’s disease. Patient-reported outcome showed inverse correlation with
endoscopic and histological activity in Crohn’s disease (rs = −0:67; rs = −0:72), while positive correlation was found in ulcerative
colitis (rs = 0:84; rs = 0:75). Interpretation and Conclusions. Patient-reported outcome is a practical and noninvasive tool for
assessment of disease activity in ulcerative colitis patients but not in Crohn’s disease.
1. Introduction
Assessment of inflammatory bowel disease (IBD) activity is
necessary in order to determine adequate therapeutic
approach for these patients. In everyday clinical practice,
assessment is based on laboratory analyses, endoscopic and
histological evaluation, and the patient’s reported outcome
(PRO) [1–4].
Because IBD is a chronic inflammatory disease with
periods of relapse and remission, disease monitoring using
clinical activity indexes is of great importance. Active inflam-
matory bowel disease in both ulcerative colitis (UC) and
Crohn’s disease (CD) with colonic involvement includes,
as per definition, presence of rectal bleeding (RB) and
diarrhoea. In recent years, several questionnaires have been
developed, bearing inmind that PRO represents an important
endpoint andmajor therapeutic goal of IBD [5]. Furthermore,
in order to avoid unpleasantness of bowel preparation and
repeated ileocolonoscopies, as well as to avoid additional
costs, noninvasive methods as well-designed questionnaires
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are required in monitoring the disease activity. Previously
published studies suggested discrepancies between PRO
and endoscopic and histological disease activity in patients
with UC [6–9]. Studies conducted in CD patients investi-
gated a two-item PRO (PRO-2) with stool frequency (SF)
and abdominal pain (AP), while a three-item PRO (PRO-3)
included additional general well-being [5, 10].
Endoscopic activity of IBD is assessed using previously
validated endoscopic scores. The endoscopic scoring system
is designed as an objective tool for monitoring andmeasuring
severity of IBD activity [11, 12]. The Mayo scoring system
(MS) is the most frequently used endoscopic activity score
designed for UC and consists of the assessment of granula-
tion scattering, vascular pattern, vulnerability, and mucosal
damage [12, 13]. The Simple Endoscopic Score for Crohn’s
disease (SES-CD) takes into account four parameters
(presence of ulcers, percentage of ulcerated surfaces, affected
surface, and presence of strictures) that need to be scored in
five bowel segments (the rectum, sigmoid and left colon,
transverse colon, right colon, and ileum) [14, 15].
Additionally, histological activity is based on the analysis
of architectural abnormalities and presence of inflammatory
features. In UC, histological examination of mucosa may
reveal crypt distortion, atrophy, Paneth metaplasia, and dif-
fuse mucosal inflammatory infiltrate, while basal plasmacy-
tosis could suggest a severe chronic inflammation [16, 17].
Histological changes in CD are usually focal and discontinu-
ous with chronic active mucosal inflammation along trans-
mural lymphoid hyperplasia. Sometimes the architectural
distortion of CD can be similar to UC, while granuloma
can be detected in some, but not all, CD patients [16]. Histo-
logical scoring systems rely on the analysis of haematoxylin
and eosin- (H&E-) stained sections using a stepwise or
numerical system [16, 18]. The most widely used score for
UC is the Geboes score, a six-grade classification system for
inflammation (0: structural change only, 1: chronic inflam-
mation, 2: neutrophils in the lamina propria, 3: neutrophils
in the epithelium, 4: crypt destruction, and 5: erosions or
ulcers) [18].
The aim of our study was to determine possible asso-
ciation between a two-item PRO based on stool frequency
and rectal bleeding (PRO-2) and endoscopic and histolog-
ical activity in patients with ulcerative colitis and colonic
Crohn’s disease.
2. Materials and Methods
2.1. Patients. We conducted a cross-sectional study at the
clinic for gastroenterology and hepatology, Clinical Centre
of Serbia, Belgrade, in 159 newly diagnosed IBD patients
(96 UC and 63 CD with colonic involvement) from 2016
until 2018. In all patients, IBD was diagnosed using clinical,
endoscopic, radiological, and histological criteria for IBD
diagnosis. We excluded patients with CD ileitis (L1), proxi-
mal disease location (L4), and indeterminate IBD. This study
was approved by the Institutional Review Board and con-
ducted in accordance with the Helsinki Declaration after
patients signed written informed consent.
2.2. Patient-Reported Outcome Measures in Inflammatory
Bowel Disease. The patient-reported outcome (PRO-2)
included evaluation of stool frequency (SF) and a rectal
bleeding (RB) subscore on 3 consecutive days in a week
before colonoscopy, excluding the day when bowel cleaning
for colonoscopy was performed. The SF subscore was
graded as follows: scores 0 (for normal number of stools),
1 (1-2 stools more than normal), 2 (3-4 stools more than nor-
mal), and 3 (5 or more stools more than normal). The RB
subscore was determined with values 0 (no blood seen), 1
(streaks of blood with the stool less than half the time), 2
(obvious blood with the stool most of the time), and 3 (blood
alone passed).
2.3. Endoscopic Evaluation of Patients with Inflammatory
Bowel Disease. All ileocolonoscopies were performed by
two experienced gastroenterologists using Olympus high-
definition colonoscopes. Endoscopic disease activity was
reported using endoscopic scoring systems (Mayo scoring
system for UC and Simple Endoscopic Score for CD). Inac-
tive ulcerative colitis disease was graded as Mayo score 0/1,
while the SES-CD index was interpreted as follows: score less
than 2 indicated inactive, 3-6 mildly active, 7-16 moderately
active, and over 16 severely active disease.
2.4. Histological Assessment of Inflammatory Bowel Disease
Activity. Histological activity was assessed using the Geboes
grading system. The score ranged from 0 to 5.4, with higher
scores indicating more severe histological inflammation [6].
Although target biopsies were taken from regions of endo-
scopic activity in CD patients and assessed for histological
activity, the use of histological scoring in Crohn’s disease
was limited by discontinuous bowel involvement.
2.5. Theory. Further studies to determine validated PRO
accuracy and utility in the assessment of IBD activity are
needed for comprehensive research in which correlation
between patients’ reported symptoms and endoscopic and
histological disease activity will be analysed on clinically
well-characterized subgroups of IBD patients. A “more per-
sonalized” approach including patients’ reported symptoms
in a validated PRO could be beneficial for more efficient
management of the disease and better prognosis.
2.6. Calculation. Statistical analyses were performed using
SPSS software version 23 (Chicago, IL). Descriptive data were
expressed as mean values, standard deviations, median, and
range for continuous measures or percentage of a group for
discrete measures. Numeric data were tested for normal dis-
tribution using the Kolmogorov-Smirnov test. One-way
ANOVA and the Kruskal-Wallis test were used to assess dif-
ferences between groups. Categorical data were analysed
using the Pearson chi-square test. The correlation between
the observed parameters was analysed using Spearman’s
correlation coefficients. p < 0:05 was required to reject the
null hypothesis.
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3. Results
Our study included 159 IBD patients (96 with ulcerative coli-
tis and 63 with Crohn’s disease). Patients’ characteristics are
summarized in Table 1.
3.1. Evaluation of Endoscopic and Histological Measures in
Study Population. No significant differences were found
between patients with different disease extension of UC in
respect of MS and histological activity (Table 2) (p = 0:641
and p = 0:595, respectively). The Mayo endoscopic score cor-
related with the degree of histological activity (Spearman
coefficient rs = 0:914) regardless of the disease localization
(Table 3). All patients with CD included in the study had
SES − CD score > 2 (active disease) and mean value 13:50 ±
10:82 for colitis and 19:35 ± 14:61 for ileocolitis. Although
SES-CD was higher in patients with more extensive disease,
no correlation was observed between SES-CD and the histo-
logical activity of disease regardless the disease localization
(Table 4).
3.2. Patient-Reported Outcome Assessment. Tables 5 and 6
summarize the relationship of symptom scores SF and RB
with endoscopic activity score in the CD and UC groups.
Subscores of SF, RB, and SF+RB in comparison with MS
showed higher values of sensitivity, specificity, and positive
predictive value (PPV) than in cases with CD patients and
the SES-CD score. Statistically significant association was
found between endoscopic and histopathological activities
in ulcerative colitis with patient-reported outcome symp-
toms (rs = 0:84 and rs = 0:75, respectively). Nevertheless,
we noticed that PRO showed inverse correlation with the
SES-CD score and histological activity in Crohn’s disease
patients (rs = −0:67 and rs = −0:72, respectively).
4. Discussion
The Mayo endoscopic activity index is a practical tool, which
could be used for objective assessment of mucosal healing in
UC. However, results of our study have not shown such cor-
relation between values of the SES-CD score and histological
activity. Geboes and Dalle noticed that when the extent of
disease needs to be defined, biopsies may double the yield
of pathology compared to endoscopic findings of inflamma-
tion in IBD [18]. As reported by previous studies, variable
results have been found comparing endoscopy scores and
histological activity [2, 6]. In the study of Geboes et al., corre-
lation between endoscopy and histology was found for endo-
scopically inflamed mucosa; however, data for mucosa
without inflammation were inconsistent [17, 19]. Persistent
microscopic lesions in the absence of endoscopic findings
may indicate likelihood of relapse in ulcerative colitis [19].
In the review article by Travis et al., they suggested that
microscopic healing in UC is a better predictor of durable
remission and expected time to next relapse, when compared
to endoscopy finding [19]. Indicators of acute mucosal
inflammation were associated with increased risk of UC
relapse [20, 21]. According to various multicentric studies,
the use of the SES-CD score has been validated for the endo-
scopic activity assessment of Crohn’s disease [12, 15]. In par-
ticular, the prospective study of Bryant et al. analysed data
from 86 patients with Crohn’s disease from 2005 until 2007
and found that SES-CD and Crohn’s Disease Endoscopic
Index of Severity (CDEIS) significantly correlate with the
clinical activity of CD [15]. During the SES-CD index valida-
tion in the Daperno et al. study, significant correlation was
reported between the index and the activity of CD [13].
As reported by consensus recommendations, endoscopic
mucosal healing is defined as a resolution of visible inflam-
mation and ulceration at endoscopy, variably Mayo 0 or 1
[17]. Often, endoscopic mucosal healing does not reflect qui-
escent microscopic disease. Numerous studies have demon-
strated that histological inflammation persists in 16–100%
of cases of endoscopically quiescent IBD [17, 21, 22]. The
values of histopathological scores in IBD can often vary
depending on the number, quality, and distribution of the
samples taken. It is necessary to analyse the basal part of
the mucosa, which is possible with cut biopsies, to allow the
surface and the deep part of the biopsy to be identified in per-
pendicular sections [23]. Since the 1950s, many histopatho-
logical scores have been used for the disease activity
assessment in UC. In the Mosli et al. systematic review, 22
histological scoring systems have been described for UC
[16]. The first histological index of activity was described in
1956 by Truelove and Richards in a study that obtained 111
serial biopsy specimens from 42 UC patients [23]. One of
the most widely used histopathological scores of disease
activity in UC is the Geboes index which includes the assess-
ment of architectural change, lamina propria neutrophils and
eosinophils, neutrophils in the epithelium, crypt destruction,
and erosion or ulceration [18].
In our study, the Geboes score was used and assigned to
biopsies ranging from 0 to 5.4, with higher scores indicating
more severe inflammation. However, there was no grading
for basal plasmacytosis in the scoring system. The use of his-
tological activity score in CD is limited by its segmentary
nature, so target biopsies were required for the assessment,
although transmural inflammation could only be analysed
in resections. The validation of histological scoring in IBD
remains challenging, and adequate assessment will require
further regression analysis of specific histological features.
Table 1: Characteristics of the patients with inflammatory bowel
disease.
UC (N = 96) CD (N = 63)
N (%) N (%)
Gender (males) 47 (48.9) 40 (63.5)
Mean age ± SD 42 ± 11 38 ± 11
Smokers 52 (54.2) 45 (71.4)
Family history of IBD 1 (1.0) 3 (4.7)
Appendectomy 2 (2.0) 10 (15.8)
Localization of the disease
E1 (proctitis) 16 (16.7) L2 (colonic) 16 (25.4)
E2 (left side) 21 (21.9) L3 (ileocolonic) 47 (74.6)
E3 (extensive colitis) 59 (61.4)
Patients with CDwithout colonic involvement were excluded from the study.
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Osada et al. investigated the correlation between endo-
scopic and histological findings in 54 UC patients and found
highly significant positive correlation in the region of the dis-
tal colon (rectum and sigma). But despite the positive corre-
lation, their results showed that a site with endoscopic score 0
can often show evidence of histological disease activity [24].
According to the data of our study, there was no significant
difference in endoscopic and histological activity scores
related to distribution of the disease in UC patients. Previous
studies have also suggested that the endoscopic appearance of
IBD alone tends to underestimate the extent of disease rela-
tive to histological evaluation [21, 22].
However, endoscopic assessment of inflammation in CD
has a better correlation with transmural inflammation than
mucosal biopsy and thus the severity and extent of inflamma-
tion [15]. In concordance with previous studies, the discrep-
ancy between endoscopy and histology findings is smaller in
the case of active disease and greater for remissive IBD.
Recently, a “treat to target” approach has been proposed
in IBD patients, and it includes a combination of PRO and
endoscopic/histological assessments as treatment targets.
Measures of PRO are based on standardized questionnaires
reflecting the patient’s perspective on their health condition
[4, 25]. Colombel et al. found that symptom subscores in
PRO correlate well with MS [5]. Nevertheless, presence of
histological inflammation in the setting of endoscopic heal-
ing can be an underlying cause of clinical symptoms in IBD
[26]. Inflammatory features in UC contribute to the changes
in muscular organisation of the bowel wall reflecting struc-
tural and functional damage with absorptive modifications
[26]. In CD, excessive deposition of extracellular matrix pro-
teins beyond the mucosal layer may lead to intestinal wall
stiffness, short bowel, colonic dysmotility, and anorectal dys-
function and additionally contribute to increased SF [27].
Our current study included newly diagnosed IBD patients
without prior therapy, and PRO symptom subscores showed
higher sensitivity, specificity, and positive predictive value
with MS in UC patients than in the CD group. Although
statistically significant association was found between
endoscopic and histopathological activities in UC with
patient-reported outcome symptoms, PRO showed inverse
correlation with the SES-CD score and histological activity
in Crohn’s disease patients. Inverse correlation could be
explained by the small bowel involvement in the majority
of CD patients, with 47 cases of ileocolitis without possible
signs of rectal bleeding and normal stool frequency and only
16 patients with CD colitis.
In 2018, a meta-analysis on the diagnostic accuracy of
PRO in UC patients with endoscopic remission reported
normal values of RB and SF subscores associated with endo-
scopic remission. Nevertheless, many patients were regis-
tered with abnormal stool frequency despite UC endoscopic
remission [28]. Patients with persistent symptoms with no,
or minimal, bowel inflammation indicate possible high prev-
alence of irritable bowel syndrome (IBS) in the IBD cohort
associated with adverse PRO.
Morris et al. investigated the predictive ability of Crohn’s
disease activity index (CDAI) for endoscopic disease activity.
Although the inclusion of biomarkers, fecal calprotectin, and
high sensitivity C-reactive protein improved prediction abil-
ity, intraindividual estimation highlighted the PRO model as
superior in prediction of CD endoscopic activity [28]. In a
large cross-sectional study published in 2016 investigating
Table 2: Impact of UC location on Mayo endoscopic score and Geboes score in study population.
Location of disease (Montreal)
UC patients Proctitis (n = 16) Left side colitis (n = 21) Extensive colitis (n = 59) p value
MS (mean ± SD) 1:93 ± 0:85 1:86 ± 0:79 2:05 ± 0:86
p = 0:641a
Med (range)
2 2 2
1-3 1-3 1-3
Geboes score (mean ± SD) 3:88 ± 1:06 3:64 ± 1:17 3:81 ± 1:32
p = 0:595a
Med (range)
4.1 4.15 4.20
2.1-5.1 2.1-5.1 1.2-5.2
Statistical significance aKruskal-Wallis test.
Table 3: Correlation of Mayo endoscopic score and histological
activity in UC patients.
Mayo score-Geboes score Spearman’s rho (rs) p value
Overall 0.914 p ≤ 0:001∗
Proctitis 0.912 p ≤ 0:001∗
Left-side colitis 0.905 p ≤ 0:001∗
Extensive colitis 0.910 p ≤ 0:001∗
∗Correlation level was measured using nonparametric Spearman’s test and
presented with correlation coefficient (rs). p < 0:05 was considered
significant.
Table 4: Correlation of SES-CD score and histological activity in
CD patients.
CES score-Geboes score Spearman’s rho p value
Overall 0.182 p > 0:05
Colitis 0.003 p > 0:05
Ileocolitis 0.182 p > 0:05
Correlation level was measured using nonparametric Spearman’s test and
presented with correlation coefficient (rs). p < 0:05 was considered
significant.
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medication use in IBD patients according to their age and
associations with PROs, older CD patients had higher con-
tinued steroid use related to worsened patient-reported out-
comes [29]. de Jong et al. identified so far more than twenty
patient-reported outcome measures (PROMs) used in clini-
cal practice for CD and UC monitoring [30]. The conducted
studies emphasized the need of further studies to determine
PRO accuracy and utility in the assessment of IBD activity.
5. Conclusion
Validated PRO models contribute to a more comprehensive
display of IBD burden establishing discrepancies between
clinical symptoms and presence of inflammation determined
by colonoscopy or histopathology. According to results of
our study, PRO-2 correlated with endoscopic and histologi-
cal activity in UC while inverse correlation was found in
CD. Higher sensitivity, specificity, and PPV of PRO-2 were
registered in UC. Our results demonstrate that PRO-2 could
be used in everyday clinical practice as a simple, noninvasive
tool of disease assessment.
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